2022 Participants

Home » 2022 Participants

Discover who attended BioFIT 2022

2022 Sponsors

Platinum sponsors

Globe Linkedin Twitter Facebook Instagram

Merck

We deliver the industry’s most comprehensive portfolio of high-quality products, services and testing for biopharmaceutical manufacturing.

We are proud to provide drug manufacturers with process development expertise and technologies, such as continuous bioprocessing.

We collaborate with the world’s leading drug developers to help bring drug therapies to patients. We bring our pharmaceutical and biotechnology expertise and products to improve every step of the manufacturing process, while providing startups with holistic support to build and scale up theirs.

Merck’s presentation « A holistic approach to speed up upstream process development for the production of biopharmaceuticals »
Speakers:
• Alexandre Laly, Customer Application Consultant – Emerging Biotech – France / BeNeLux / Switzerland
• Sarah Timp, Technical Application Consultant for Upstream Processing
Wednesday, November 30th | 10.30 – 11.00 am | Innov’Area

Globe Linkedin Twitter Facebook Instagram

Sanofi

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our teams across the world strive to transform the practice of medicine, turning the impossible into the possible for patients. We provide potentially life-changing treatments and the protection of life-saving vaccines to millions of people, and affordable access to our medicines in some of the world’s poorest countries.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Sanofi’s presentation “Why partner with Sanofi?”
Speaker: Murielle Gitton, Head R&D Transactions
Tuesday, November 29th | 3.15 – 3.30 pm | Innov’Area

Globe Linkedin Twitter Facebook Instagram

Sartorius

Sartorius Stedim Biotech is a leading partner of the biopharma industry. Our solutions are supporting our customers to produce drugs safely, timely and economically. The key product categories of our company are cell cultivation, fermentation, filtration, purification, and fluid management.

Sartorius’ presentation « Cell culture media and testing solution capabilities »
Speaker: Luka Kadovic, Field Application Specialist CMTS
Wednesday, November 30th | 11.45 am – 12.00 pm | Madrid 1 room

Globe Linkedin Twitter Facebook Instagram

Zoetis

As the world’s leading animal health company, we are driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After 70 years innovating ways to predict, prevent, detect, and treat animal illness, we continue to stand by those raising and caring for animals worldwide – from livestock farmers to veterinarians and pet owners. A Fortune 500 company, we generated revenue of $7.8 billion in 2021 with ~12,100 employees. For more, visit www.zoetis.com.

Zoetis’ presentation « Innovation and One Health: How can monoclonal antibodies offer new perspectives in veterinary medicines? »
Speakers:
• Olivier Martinon, Vice President External Innovation & Research Alliances and LIBRELA Project Leader
• Hervé de Cidrac, Senior Vice President General Manager Cluster France
Tuesday, November 29th | 2.00 – 3.00 pm | Madrid 1 room

Silver sponsors

Globe Linkedin Twitter Facebook Instagram

Boehringer Ingelheim

Boehringer Ingelheim International

Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. More than 52,000 employees serve over 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.

Boehringer Ingelheim Animal Health

As a global leader in the animal health industry our more than 10,000 employees serve more than 150 markets worldwide. We are one of the largest providers of vaccines, parasiticides and therapeutics. With a strong presence in the companion animal and livestock segments, we support veterinarians, farmers as well as pet and horse owners. As part of family-owned Boehringer Ingelheim, we are rooted in our family values and take a long-term perspective.

Globe Linkedin Twitter Facebook Instagram

FINDMED

FINDMED is a consortium of 18 French leading research institutions involved in healthcare at large and that have got the “Carnot” label for their ability to conduct R&D partnerships with companies . FINDMED’s mission is to help French companies, in particular start-up and SMEs, to access the expertise and the technological platforms of its members. FINDMED is therefore companies’ R&D partner for their innovation projects, whether they be biotech and/or medtech.

Globe Linkedin Twitter Facebook Instagram

GENFIT

GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases characterized by high unmet medical needs. GENFIT is a pioneer in the research and development of therapeutic and diagnostic solutions in liver diseases, with a rich history and strong scientific heritage spanning more than two decades. Thanks to its expertise in bringing early-stage assets with high potential to late development and pre-commercialization stages, today GENFIT boasts a growing and diversified pipeline of innovative therapeutic and diagnostic solutions.

Globe Linkedin Twitter Facebook Instagram

Servier

Servier is a global independent pharmaceutical group governed by a Foundation. With a strong international presence in 150 countries and a total revenue of 4.7 B€ in 2021, Servier employs 21,800 people worldwide. To accelerate therapeutic innovation for the benefit of patients, the Group is committed to open and collaborative innovation with academic partners, pharmaceutical groups, and biotech companies. Servier growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology, neurosciences and immuno-inflammatory diseases.

More information: www.servier.com

Bronze sponsors

Globe Linkedin Twitter Facebook Instagram

ACROBiosystems

ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and health industries by providing products and business models innovation.

The company spans across the globe and maintains offices, R&D centers, and production bases in 12 different cities within the United States, Switzerland, England, Germany, and China.

Globe Linkedin Twitter Facebook Instagram

Capital Grand Est

Capital Grand Est is an asset management company based in Strasbourg – France.
The company manages over €180M.
Capital Grand Est is mainly focused on investing in growing SMEs and promising young Start-Ups located in the eastern part of France.

Globe Linkedin Twitter Facebook Instagram

Ipsen

Ipsen is a public global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease and Neuroscience. With Specialty Care sales of €2.6bn in FY 2021, Ipsen sells medicines in over 100 countries. Ipsen has 5,000 employees worldwide and innovative research located in leading biotechnological and life-science hubs in France, UK, US and China. For more information, visit ipsen.com and get in touch with our partnering team!

Globe Linkedin Twitter Facebook Instagram

MSD

MSD has a strong history of success in translating cutting-edge research into life-saving medical breakthroughs. Our scientific advances have made a difference in the lives of millions of patients worldwide… and many of these advances were the result of partnerships. In 2016, more than 60% of our human health sales were attributable to alliance partnerships and patents and we continue to work with our partners in some of the most challenging areas of biomedical research. With more than 100 business development transactions since 2015, our team has experience working on collaborations from discovery to clinical-stage programs regardless of therapeutic area or modality. We believe that by working together we can play a major role in transforming global health care. Together we can invent for life.

Globe Linkedin Twitter Facebook Instagram

Pfizer

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us.

Globe Linkedin Twitter Facebook Instagram

Pfizer CenterOne

Pfizer CentreOne® is a global CDMO within Pfizer and a leading supplier of specialty APIs. Our global manufacturing network includes more than 35 sites across six continents. Backed by Pfizer resources, we deliver technical expertise, global regulatory support and long-term supply.

Working together with our customers, we combine our knowledge with open dialogue to solve challenges. For more information, visit www.pfizercentreone.com.

Globe Linkedin Twitter Facebook Instagram

Roche

Roche is the world’s largest biotech company and #1 investor into R&D, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the CNS. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare. Our Pharma Partnering team provides comprehensive BD and alliance management support for Roche and Genentech’s R&D units and the broader pharmaceutical division. Alongside the broad internal pipeline, external innovation has always been a critical component of our R&D strategy.

Globe Linkedin Twitter Facebook Instagram

X’Prochem

X’PROCHEM is a biotech company specialised in chemical synthesis of proteins for therapeutic and diagnostic use. We are able to design and produce complex and highly customized proteins thanks to our robotic technology.

We can help you to produce proteins that are:
– Difficult to produce or to purify
– Need unnatural amino acids
– More efficient and reliable
– Proteins composed of up to 400 amino acids
– Contain a precise modification in the protein sequence

Our proteins are guaranteed:
– high purity
– No endotoxins or biological contaminants
– No isoforms

Contributing sponsors

Globe Linkedin Twitter Facebook Instagram

AdBio

AdBio partners (formerly Advent France Biotechnology) is a venture capital firm investing in early stage life sciences companies in Europe

AdBio partners’ unique strategy combines early-stage investments in promising startups and strong entrepreneurial support to enable and strengthen the company’s growth.

As an early-stage investor, we act as a catalyst to create companies based on innovations coming from academic research. We have established relationships with leading research institutions and technology transfer offices in Europe and benefit from the support of strong network of scientific, clinical, industry and financial partners.

The operational team is managed by Alain Huriez, MD, chairman, and Matthieu Coutet, managing partner; it includes seasoned investment professionals with long-standing track records in entrepreneurial ventures, combined with strong scientific and medical expertise.

Globe Linkedin Twitter Facebook Instagram

Novo Nordisk

Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. We are committed to the discovery and development of innovative treatments for diabetes, obesity, haemophilia, NASH, atherosclerosis, heart failure, chronic kidney disease as well as some rare blood or endocrine diseases. We are seeking partnerships in all these indications. From molecule to market, our focus is on the patient. We are also committed to environmental and social responsibility.